Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. User Boards ›
  4. Investors Hangout MVP's Message Board

$RVXCF back over $2 and still no news.... Lots

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 99266
(Total Views: 245)
Posted On: 07/10/2018 10:45:27 AM
Avatar
Posted By: growacet
$RVXCF back over $2 and still no news....

Lots of upcoming catalysts and inflection points....and 10 bagger potential from current levels if their PH III trial for patients with Diabetes succeeds imo.

-A 7th DSMB report and/or SSRA
Its been over 4 months now since the DSMB has chimed in, 6 times they've recommended the trial continue on with no changes recommended and no concerns listed about either safety or efficacy. An SSRA would be even better.

-Successful completion of BETonMACE and top line results. If things go reasonably close to how they seem to be planned the 250 MAC events should happen sometime late in the year.

-NDA application

-NDA approval

Each step has risks of course....but if each step is successfully achieved I like the chances for a PPS in and around the $10 mark by the EOY.

$5 with good SSRA, or maybe $3 to $4 with a 7th + DSMB report.

$10 if they're able to meet the BETonMACE primary end point with positive top-line data.

Then would come an NDA filing and hopefully approval. And obviously there could be other announcements along the way like licensing deals, the start of trials for CKD and Fabry's, further analyst coverage or media exposure.



(0)
(0)




Check out my blog if you like: Avoid The Bag




Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us